EUCTR2004-004267-30-DEActive, not recruitingNot Applicable
Efficacy and Tolerability of Dexibuprofen Film coated tablets in Comparison to Ibuprofen in Children and Adolescents with Tonsillopharyngitis - n.a.
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Gebro Pharma GmbH
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •male or female patients between 8 and 18 years of age, diagnosed tonsillopharyngitis (TPS score > 4), acute sore throat pain (moderate, severe or extreme), written informed consent/assent (parents and children/adolescents);
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •patients previously sensitive to dexibuprofen or ibuprofen, to any other NSAID, or to any excipient of the products; patients in whom substances with similar action (e.g. aspirin or other NSAIDs) precipitate attacks of asthma, bronchospasm, acute rhinitis, or causal nasal polyps, urticaria or anioneurotic oedema; patients with active or suspected gastrointestinal ulcer or history of gastrointestinal ulcer (in the past 6 months); patients who have gastrointestinal bleeding or other active bleedings or bleeding disorders; patients with Crohn´s disease or ulcerative colitis, with severe heart failure, with severe renal dysfunction (GFR < 30 ml/min), with severely impaired hepatic function, with haemorrhagic diathesis and other coagulation disorders, or patients receiving anticoagulant therapy; pregnancy; connective tissue diseases such as e.g. lupus erythematosus and other autoimmune diseases; use of analgesic, antipyretic or anti-inflammatory drugs within the last 3 days prior to entry into the trial, regular use of concomitant treatment of drugs with pharmacological effects that may modify the results of the trial (e.g. antibiotics) or use of cold medication within the past 4 hours, participation in an other clinical trial less than 30 days ago, simultaneous participation in an other clinical trial;
Investigators
Similar Trials
Active, not recruiting
Phase 1
Efficacy of the Doravirine/Tenofovir Disoproxil Fumarate/Lamivudine combination in people living with HIV with a history of M184V/I mutation and virologically controlled: a phase II, open-label, non-comparative pilot study.Patients living with HIV-1 who are virologically controlled and carry an M184V/I mutation in a previous genotypeMedDRA version: 20.1Level: LLTClassification code: 10020160Term: HIV disease Class: 10021881CTIS2023-505845-17-00Centre Hospitalier Universitaire De Caen Normandie32
Active, not recruiting
Unknown
Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B patientsEffectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B patientsInfections and InfestationsISRCTN80908109GlaxoSmithKline (China) Investment Co., Ltd.2,000
Completed
Phase 4
A comparative study of diclofenac skin patch against oral diclofenac for pain control after root canal treatmentCTRI/2017/03/008207Faculty of Dental Sciences32
Not yet recruiting
Phase 3
Comparative Study Between Diclofenac And Ketoprofen Transdermal Patch For Pain Management In Patients Undergoing Minor Oral Surgical ProceduresCTRI/2024/04/065585Dr Amir Sohail
Recruiting
Not Applicable
Efficacy and Safety of Diclofenac Suppository for Post-operative Pain Relief After Diagnostic Hystero-laparoscopy and Dye Test: A Double-blind Placebo Controlled Randomised StudyPACTR202102546768103Okam Princeston108
